

BIOMARIN PHARMACEUTICAL INC
 Form 4
 November 23, 2016

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BIENAIME JEAN JACQUES

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)
 Director 10% Owner
 Officer (give title below) Other (specify below)
 Chief Executive Officer

(Last) (First) (Middle)
C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2016

SAN RAFAEL, CA 94901

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	11/21/2016 ⁽¹⁾	11/21/2016	M	69,744 A	\$ 26.49	240,426 ⁽²⁾	D
Common Stock	11/21/2016 ⁽¹⁾	11/21/2016	S	69,744 D	\$ 87.5556 ⁽³⁾	170,682 ⁽²⁾	D
Common Stock	11/22/2016 ⁽¹⁾	11/22/2016	M	69,743 A	\$ 26.49	240,425 ⁽²⁾	D
Common Stock	11/22/2016 ⁽¹⁾	11/22/2016	S	69,743 D	\$ 85.6934	170,682 ⁽²⁾	D

(4)

Common Stock	182,801 ⁽²⁾ I	Shares held by Jean-Jacques Bienaime Family Trust
-----------------	--------------------------	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	
Stock Option (right to buy Common Stock)	\$ 26.49	11/21/2016 ⁽¹⁾	11/21/2016	M	69,744	11/12/2011 05/11/2021	Common Stock	69,744	
Stock Option (right to buy Common Stock)	\$ 26.49	11/22/2016 ⁽¹⁾	11/22/2016	M	69,743	11/12/2011 05/11/2021	Common Stock	69,743	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST.	X		Chief Executive Officer	

SAN RAFAEL, CA 94901

Signatures

/s/ Laura Randall Woodhead,
Attorney-in-Fact

11/23/2016

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the
(1) shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime.

The amount of securities beneficially owned has been updated from the reporting person's prior Form 4 to reflect (a) changes in the form of ownership due to transfers made by the reporting person between accounts held directly and indirectly in the name of the Bienaime
(2) Family Trust and the Jean-Jacques Bienaime Family Trust and (b) an additional 4,357 shares beneficially owned by the reporting person pursuant to a reconciliation of the Company's records following the completion of the transfer of shares in connection with the reporting person's marital separation agreement.

The price in column 4 is the weighted average price. The price actually received ranged from \$86.74 to \$89.59. The reporting person shall
(3) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

The price in column 4 is the weighted average price. The price actually received ranged from \$84.45 to \$88.16. The reporting person shall
(4) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

(5) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.